{
    "medicine_id": "43e715370520b352c9ad1797efd5c6883f98f2b2",
    "platform_id": "DB05478",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v Pradefovir mesylate",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use as a prodrug for Hepsera in treating hepatitis viral B",
            "contraindications": {
                "disease": "Good safety profile",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Pradefovir is activated through oxidation that is mediated by cytochrome P 450 CYP 3A4 which is predominantly expressed in the liver Accordingly pradefovir allows Hepsera to be concentrated in the liver while maintaining lower concentration levels in other tissue The novel prodrug is an orally administered small molecule compound that belongs to a novel series of phosphate and phosphonate drugs It is highly stable in both plasma and tissues",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}